L-脯氨酸甲酯 | 2577-48-2

• 物质功能分类: 分析化学 - 标准品 - 药典标准品和杂质标准品
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: L-脯氨酸甲酯
• 英文名称: L-Proline methyl ester
• 英文别名: methyl (2S)-pyrrolidine carboxylate；methyl L-prolinate；methyl prolinate；proline methyl ester；L‐proline methyl ester；methyl (2S)-pyrrolidine-2-carboxylate
• CAS: 2577-48-2
• 化学式: C₆H₁₁NO₂
• mdl: MFCD03790963
• 分子量: 129.159
• InChiKey: BLWYXBNNBYXPPL-YFKPBYRVSA-N

物化性质

• 熔点：
  151-152 °C(Solv: ethyl ether (60-29-7))
• 沸点：
  70 °C(Press: 10 Torr)
• 密度：
  1.055±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.833
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090
• 储存条件：
  存放在阴凉处，惰性气氛中，冷藏保存，温度低于-20°C。

反应信息

• 作为反应物：
  描述：

  L-脯氨酸甲酯 在 ammonium hydroxide 、 三聚氯氰 、 potassium carbonate 、 potassium iodide 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 、 丁酮 为溶剂， 反应 7.0h， 生成 维达列汀
  参考文献：
  名称：

  A Cost-Effective Method to Prepare Pure Vildagliptin

  摘要：

  一种具有成本效益的合成方法已被报道，能够在温和的实验条件下制备维达格列iptin，收率良好且纯度高。该方法以L-脯氨酸为起始物，与氯乙酰氯在四氢呋喃（THF）中成功反应，得到1-(2-氯乙酰)-吡咯烷-2-羧酸，随后在二氯甲烷（DCM）中用TCT（2, 4, 6-三氯-1, 3, 5-三嗪）处理，转化为1-(2-氯乙酰)-吡咯烷-2-氨基甲酸酯，再经过在N,N-二甲基甲酰胺（DMF）中用TCT脱水，最终转化为1-(2-氯乙酰)-吡咯烷-2-氰，后者与3-氨基金刚烷醇反应得到维达格列iptin。维达格列iptin的总收率约为48%，纯度约为99%。

  DOI：

  10.2174/1570178611310030003
• 作为产物：
  描述：

  6-hydroxymetatacarboline D 在 盐酸 、 三甲基氯硅烷 、 水 作用下， 反应 16.0h， 生成 L-脯氨酸甲酯
  参考文献：
  名称：

  HR-MALDI-MS Imaging Assisted Screening of β-Carboline Alkaloids Discovered from Mycena metata

  摘要：

  Fruiting bodies of Mycena metata were screened for the presence of new secondary metabolites by means of HPLC-UV, LC-HR-ESIMS, and high-resolution matrix-assisted laser desorption/ionization mass spectrometry imaging (HR-MALDI-MS imaging). Thus, a new beta-carboline alkaloid, 6-hydroxymetatacarboline D (1d), was isolated from fruiting bodies of M. metata. 6-Hydroxymetatacarboline D consists of a highly substituted beta-carboline skeleton, which is likely to be derived biosynthetically from L-tryptophan, 2-oxoglutaric acid, L-threonine, and L-proline. The structure of the alkaloid was established by 2D NMR spectroscopic methods and HR-ESIMS. Moreover, by extensive application of LC-HR-ESIMS, LC-HR-ESIMS/MS, and LC-HR-ESIMS3 techniques we were able to elucidate the structures of a number of accompanying beta-carboline alkaloids, 1a-1c, 1e-1i, and 2a-2g, structurally closely related to 6-hydroxymetatacarboline D, which are present in M. metata in minor amounts. The absolute configuration of the stereogenic centers of the beta-carboline alkaloids was determined by GC-MS comparison with authentic synthetic samples after hydrolytic cleavage and derivatization of the resulting amino acids.

  DOI：

  10.1021/np300455a
• 作为试剂：
  描述：

  [(6R,7S,9R)-6,9-Dimethyl-7-(2-oxo-ethyl)-1,4-dioxa-spiro[4.5]dec-6-yl]-acetaldehyde 在 六甲基磷酰三胺 、 1,2,2-三甲基环戊烷-1,3-二羧酸 、 L-脯氨酸甲酯 作用下， 以 乙醚 、 乙醇 为溶剂， 反应 24.0h， 以16%的产率得到
  参考文献：
  名称：

  Regioselective intramolecular aldol condensation by using excess morpholine-camphoric acid.

  摘要：

  在各种反应条件下，包括伍德沃德法和科里法，对I型二醛的分子内选择性醛缩合反应进行了探索。表I中给出了使用过量吗啉-樟脑酸所得到的结果，并与之前的方法所得到的结果进行了比较。还描述了通过核磁共振分析对产品进行结构分配的情况。

  DOI：

  10.1248/cpb.29.766

文献信息

• Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds
  申请人：Abbott Laboratories

  公开号：US20040116518A1

  公开（公告）日：2004-06-17

  The present invention relates to novel cinnamide compounds that are useful for treating inflammatory and immune diseases and cerebral vasospasm, to pharmaceutical compositions containing these compounds, and to methods of inhibiting inflammation or suppressing immune response in a mammal.

  本发明涉及新型肉桂酰胺化合物，用于治疗炎症和免疫性疾病以及脑血管痉挛，以及含有这些化合物的药物组合物，以及在哺乳动物中抑制炎症或抑制免疫反应的方法。
• Sterically Demanding Oxidative Amidation of α-Substituted Malononitriles with Amines Using O₂
  作者：Jing Li、Martin J. Lear、Yujiro Hayashi

  DOI：10.1002/anie.201603399

  日期：2016.7.25

  An efficient amidation method between readily available 1,1-dicyanoalkanes and either chiral or nonchiral amines was realized simply with molecular oxygen and a carbonate base. This oxidative protocol can be applied to both sterically and electronically challenging substrates in a highly chemoselective, practical, and rapid manner. The use of cyclopropyl and thioether substrates support the radical

  简单地使用分子氧和碳酸盐碱即可实现易于获得的1,1-二氰基烷烃与手性或非手性胺之间的高效酰胺化方法。该氧化方案可以高度化学选择性，实用和快速的方式应用于空间和电子挑战性底物。环丙基和硫醚底物的使用可支持α-过氧丙二腈物种的自由基形成，后者可以环化成二恶英，后者可以单价氧化丙二腈α-碳二酮以提供能够与胺亲核试剂反应的活化的酰基氰化物。
• DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE AND PHARMACEUTICALS CONTAINING THE SAME
  申请人：CHUGAI SEIYAKU KABUSHIKI KAISHA

  公开号：US20160002251A1

  公开（公告）日：2016-01-07

  The present invention provides a dihydropyridazine-3,5-dione derivative or a salt thereof, or a solvate of the compound or the salt, a pharmaceutical drug, a pharmaceutical composition, a sodium-dependent phosphate transporter inhibitor, and a preventive and/or therapeutic agent for hyperphosphatemia, secondary hyperparathyroidism, chronic renal failure, chronic kidney disease, and arteriosclerosis associated with vascular calcification comprising the compound as an active ingredient, and a method for prevention and/or treatment.

  本发明提供了一种二氢吡啶嗪-3,5-二酮衍生物或其盐，或化合物或盐的溶剂化合物，一种药物，一种药物组合物，一种钠依赖性磷酸盐转运体抑制剂，以及作为活性成分的化合物的高磷血症、继发性甲状旁腺功能亢进症、慢性肾功能衰竭、慢性肾病和与血管钙化相关的动脉硬化的预防和/或治疗剂，以及预防和/或治疗的方法。
• [EN] AZADECALIN DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION<br/>[FR] DÉRIVÉS D'AZADÉCALINE EN TANT QU'INHIBITEURS DE LA RÉPLICATION DU VIRUS DE L'IMMUNODÉFICIENCE HUMAINE
  申请人：VIIV HEALTHCARE UK (NO 5) LTD

  公开号：WO2018002848A1

  公开（公告）日：2018-01-04

  Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, azadecaline derivatives that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formula (I). These compounds are useful for the treatment of HIV and AIDS.

  具有药物和生物影响特性的化合物，其药物组合物和使用方法已列出。具体来说，提供了具有独特抗病毒活性的阿扎德卡林衍生物，作为HIV成熟抑制剂，如化合物(I)的公式所代表的那样。这些化合物对于治疗HIV和艾滋病是有用的。
• Antimicrobial activity, biocompatibility and hydrogelation ability of dipeptide-based amphiphiles
  作者：Rajendra Narayan Mitra、Anshupriya Shome、Pritha Paul、Prasanta Kumar Das

  DOI：10.1039/b815368j

  日期：——

  The development of new antibiotics is of increasing importance due to the growing resistance power of microbes against conventional drugs. To this end, cationic peptides are emerging as clinically potent antimicrobial agents. In the present study, we have synthesized six dipeptide-based cationic amphiphiles with different head group structures by varying combinations of L-amino acid residues. These amphiphiles showed remarkable growth inhibiting activity on several Gram-positive (minimum inhibitory concentration (MIC) = 0.1–10 µg/mL) and Gram-negative (MIC = 5–150 µg/mL) bacteria as well as on fungus (MIC = 1–50 µg/mL). The inherent antimicrobial efficacies of these cationic dipeptides were influenced by the head group architecture of the amphiphiles. Encouragingly, these amphiphiles selectively attacked microbial cells, while showing biocompatibility toward mammalian cells. The results show that the rational designing of short peptide-based cationic amphiphiles might serve as a promising strategy in the development of antimicrobial agents with greater cell specificities. In addition, the amphiphiles showed water gelation ability at room temperature. The formation of non-covalent supramolecular networks in gelation was established by microscopic and spectroscopic studies.

  由于微生物对传统药物的耐药能力不断增强，新型抗生素的研发日益重要。为此，阳离子肽作为一种临床有效的抗菌剂正在崭露头角。在本项研究中，我们通过改变L-氨基酸残基的组合，合成了六种具有不同头部结构的双肽基阳离子两亲性分子。这些两亲性分子对多种革兰氏阳性菌（最低抑制浓度（MIC）= 0.1–10 µg/mL）、革兰氏阴性菌（MIC = 5–150 µg/mL）以及真菌（MIC = 1–50 µg/mL）显示出显著的生长抑制活性。这些阳离子双肽的固有抗菌功效受到两亲性分子头部结构的影响。令人鼓舞的是，这些两亲性分子选择性地攻击微生物细胞，同时对哺乳动物细胞表现出生物相容性。结果表明，合理设计基于短肽的阳离子两亲性分子可能是开发具有更高细胞选择性的抗菌剂的潜在策略。此外，这些两亲性分子在室温下具有水凝胶化能力。通过显微镜和光谱学研究，建立了凝胶化中非共价超分子网络的形成。